PRESS RELEASE

nDatalyze Corp. ("NDAT" or the "Corporation") (CSE:NDAT) (OTC:NDATF) announces a private placement and provides an update by its new President, Joshua Hill.

Calgary, Alberta – April 18, 2024

For Immediate Release – nDatalyze Corp. ("NDAT" or the "Corporation") (CSE:NDAT) (OTC:NDATF) is pleased to announce an arm's-length private placement ("PP") of 1,000,000 common shares ("Shares") at US$0.15 per Share (US$150,000). At a 1.375 exchange rate this equates to approximately $206,250 Canadian Dollars and $0.21 per Share subscription price. A 6% finders fee of US$9,000 will be paid in cash to a third party and 90% of the net proceeds will be allocated to the recently-acquired Mindbalanced Inc. ("MB") operations (NDAT acquired 100% of MB on April 16, 2024). The remainder will be used for general working capital. There are no warrants or rights attached to the Shares and the Shares will be subject to a minimum four month hold period. The PP is subject to usual Board and Regulatory approvals.

Joshua Hill, President, reports: "Gone are the days of "one-size-fits-all" mental condition treatments that too often result in poor patient outcomes. Our multivariate service provides personalized treatment protocols by integrating advanced machine-learning assessment tools, genetics-based drug interaction panels and FDA-cleared, non-invasive, and non-drug-dependent treatment protocols using Transcranial Magnetic Stimulation ("TMS"). Our primary customers are mental health-related facilities, clinics and clinicians who want to provide effective and personalized treatment plans for drug-resistant patients. We manage the entire program and our revenue-sharing business model benefits our customers by saving time, providing state-of-the-art tools, offering personalized treatment protocols, and adding an additional revenue stream. We expect that revenues from private and public medical insurance programs will grow significantly as mental health benefits are added to more insurance plans. Importantly, we expect to add significant amounts of biometric, DNA, and TMS treatment response data to YMI which we believe will be invaluable in developing personalized treatment protocols going forward. All of this adds up to high levels of interest from all levels of our market."

MB also reports that Dr. Laura Champagne, Psychiatrist from Texas, and Dr. Yvonka De Ridder from Florida, have recently joined our esteemed team through signed contracts.

For Further Information about this transaction, please contact:

Joshua Hill, President
Email: josh@mindbalanced.org
Mindbalanced website: https://mindbalanced.org/
nDatalyze website: https://www.ndatalyze.com

About Mindbalanced, Inc.: Mindbalanced's vision is to redefine mental healthcare through an integrative, personalized approach leveraging cutting edge technology and non-invasive treatment protocols. By harnessing evidence-based data we aim to predict and enhance mental wellbeing, taking

into account individual predispositions and environmental factors thereby fostering healthier and more fulfilling lives for all.

About YMI: YMI uses evidence-based, objective data from whole life experiences to predict individual mental states over time and applies this knowledge towards a fuller understanding of how mental health develops, and how to improve mental wellbeing. YMI combines supervised machine-learning with a proprietary Reference Database to predict an individual's predisposition toward a variety of common mental conditions, both current and forward in time. YMI is poised to revolutionize mental health diagnoses while ensuring a sustainable revenue stream. By strategically addressing the causes of misdiagnosis, establishing credibility through clinical studies, and targeting key markets, YMI aligns both societal impact and financial success.